share_log

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

Organovo Holdings, Inc. 宣布525万美元的公开募股定价
GlobeNewswire ·  05/08 20:00

SAN DIEGO, May  08, 2024  (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the pricing of a public offering consisting of 6,562,500 shares of common stock (or pre-funded warrants in lieu thereof) and common warrants to purchase up to an aggregate of 6,562,500 shares of its common stock, at a combined public offering price per share of common stock and accompanying common warrant to purchase one share of common stock of $0.80 (or $0.799 per share subject to pre-funded warrants and accompanying warrant to purchase one share of common stock).

圣地亚哥,2024年5月8日(GLOBE NEWSWIRE)——专注于开发基于三维(3D)人体组织临床前景的新型治疗方法的临床阶段生物技术公司Organovo Holdings, Inc.(纳斯达克股票代码:ONVO)(“Organovo” 或 “公司”)今天宣布了由6,562,500股普通股(或代替其的预筹认股权证)和普通认股权证组成的公开发行定价按普通股每股公开发行价格总共购买最多6,562,500股普通股股票和随附的普通认股权证,用于购买一股普通股0.80美元(或每股0.799美元,但需购买一股普通股的预先融资认股权证和附带的认股权证)。

The common warrants will have an exercise price of $0.80 per share, will be immediately exercisable upon issuance and have a term of five years after their original issuance date. The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, are expected to be $5.25 million (excluding any proceeds that may be received upon the exercise of the common warrants). The offering is expected to close on or about May 13, 2024, subject to the satisfaction of customary closing conditions.

普通认股权证的行使价为每股0.80美元,发行后可立即行使,有效期为原发行日期后的五年。在扣除配售代理费和公司应付的其他发行费用之前,本次发行的总收益预计为525万美元(不包括行使普通认股权证时可能获得的任何收益)。此次发行预计将于2024年5月13日左右结束,但须满足惯例成交条件。

JonesTrading Institutional Services LLC ("Jones") is acting as the exclusive placement agent for the offering.

JonesTrading机构服务有限责任公司(“琼斯”)是本次发行的独家配售代理。

The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-278668), as amended, that was declared effective by the Securities and Exchange Commission (the "SEC") on May 8, 2024. The offering is being made only by means of a prospectus forming part of the effective registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC's website at http://www.sec.gov and may also be obtained, when available, by contacting Jones, 325 Hudson Street, 6th Floor, New York, New York 10013, or by telephone at (212) 907-5332, or by email at JTCM@jonestrading.com.

上述证券是根据经修订的S-1表格(文件编号333-278668)上的注册声明发行的,该声明于2024年5月8日由美国证券交易委员会(“SEC”)宣布生效。此次发行仅通过招股说明书进行,该招股说明书是与本次发行有关的有效注册声明的一部分。与本次发行有关的初步招股说明书已提交给美国证券交易委员会。最终招股说明书的电子副本(如果有)可在美国证券交易委员会的网站 http://www.sec.gov 上获得,也可以在可用时通过联系纽约州哈德逊街325号6楼的琼斯获得,或致电(212)907-5332,或发送电子邮件至 JTCM@jonestrading.com 获取。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

本新闻稿不构成出售要约或招揽购买这些证券的要约,在根据任何此类州或司法管辖区的证券法进行注册或资格认证之前,此类要约、招标或出售是非法的州或司法管辖区也不得出售这些证券。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发